Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the twelve brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $25.4444.
A number of brokerages have recently issued reports on ARCT. B. Riley Financial began coverage on Arcturus Therapeutics in a report on Wednesday, March 18th. They set a “buy” rating and a $22.00 price objective for the company. Piper Sandler cut their price target on Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday, March 4th. Citigroup cut their price target on Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating for the company in a research note on Thursday, March 5th. Weiss Ratings upgraded Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, April 21st. Finally, Roth Mkm initiated coverage on Arcturus Therapeutics in a research note on Thursday, January 22nd. They issued a “buy” rating and a $20.00 price target for the company.
View Our Latest Stock Report on ARCT
Arcturus Therapeutics Stock Down 4.6%
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.08. Arcturus Therapeutics had a negative return on equity of 36.55% and a negative net margin of 143.80%.The company had revenue of $2.06 million during the quarter, compared to analysts’ expectations of $6.30 million. Equities research analysts expect that Arcturus Therapeutics will post -4.17 earnings per share for the current year.
Institutional Investors Weigh In On Arcturus Therapeutics
Several institutional investors have recently made changes to their positions in ARCT. ARK Investment Management LLC boosted its stake in shares of Arcturus Therapeutics by 39.4% in the fourth quarter. ARK Investment Management LLC now owns 2,611,099 shares of the biotechnology company’s stock valued at $16,006,000 after buying an additional 738,378 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in shares of Arcturus Therapeutics by 1,371.4% in the third quarter. Arrowstreet Capital Limited Partnership now owns 552,179 shares of the biotechnology company’s stock valued at $10,177,000 after buying an additional 514,652 shares during the period. Millennium Management LLC bought a new stake in shares of Arcturus Therapeutics in the first quarter valued at approximately $4,892,000. Bank of America Corp DE boosted its stake in shares of Arcturus Therapeutics by 112.0% in the third quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company’s stock valued at $11,428,000 after buying an additional 327,626 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Arcturus Therapeutics by 12.9% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,288,935 shares of the biotechnology company’s stock valued at $17,671,000 after buying an additional 262,347 shares during the period. 94.54% of the stock is currently owned by institutional investors.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.
The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.
Read More
- Five stocks we like better than Arcturus Therapeutics
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
- MarketBeat Week in Review – 05/11 – 05/15
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
